Zurcher Kantonalbank Zurich Cantonalbank Has $437,000 Position in Neurocrine Biosciences, Inc. (NBIX)

Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 7.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,116 shares of the company’s stock after purchasing an additional 448 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Neurocrine Biosciences were worth $437,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. FMR LLC increased its holdings in Neurocrine Biosciences by 0.5% during the 2nd quarter. FMR LLC now owns 13,451,201 shares of the company’s stock worth $1,321,446,000 after acquiring an additional 60,325 shares during the period. Raymond James & Associates increased its holdings in Neurocrine Biosciences by 11.9% during the 2nd quarter. Raymond James & Associates now owns 10,393 shares of the company’s stock worth $1,021,000 after acquiring an additional 1,109 shares during the period. Advisors Asset Management Inc. bought a new stake in Neurocrine Biosciences during the 2nd quarter worth approximately $334,000. United Services Automobile Association increased its holdings in Neurocrine Biosciences by 5.5% during the 2nd quarter. United Services Automobile Association now owns 14,853 shares of the company’s stock worth $1,459,000 after acquiring an additional 774 shares during the period. Finally, Fox Run Management L.L.C. bought a new stake in Neurocrine Biosciences during the 3rd quarter worth approximately $234,000. Hedge funds and other institutional investors own 97.82% of the company’s stock.

In other news, Director Richard F. Pops sold 4,123 shares of the company’s stock in a transaction on Monday, November 12th. The shares were sold at an average price of $103.30, for a total value of $425,905.90. Following the completion of the sale, the director now owns 33,636 shares of the company’s stock, valued at approximately $3,474,598.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Kyle Gano sold 3,809 shares of the company’s stock in a transaction on Tuesday, February 5th. The shares were sold at an average price of $88.12, for a total transaction of $335,649.08. Following the completion of the sale, the insider now directly owns 17,595 shares of the company’s stock, valued at approximately $1,550,471.40. The disclosure for this sale can be found here. In the last three months, insiders sold 22,705 shares of company stock valued at $2,071,790. Corporate insiders own 4.30% of the company’s stock.

A number of research firms recently weighed in on NBIX. ValuEngine raised shares of Neurocrine Biosciences from a “hold” rating to a “buy” rating in a report on Friday. BidaskClub lowered shares of Neurocrine Biosciences from a “hold” rating to a “sell” rating in a report on Saturday. Zacks Investment Research lowered shares of Neurocrine Biosciences from a “buy” rating to a “hold” rating in a report on Saturday. Canaccord Genuity began coverage on shares of Neurocrine Biosciences in a report on Wednesday, November 21st. They set a “buy” rating and a $111.00 target price on the stock. Finally, Oppenheimer set a $140.00 target price on shares of Neurocrine Biosciences and gave the stock a “buy” rating in a report on Monday, November 5th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $102.28.

NBIX stock opened at $84.39 on Friday. Neurocrine Biosciences, Inc. has a one year low of $64.72 and a one year high of $126.98. The company has a market capitalization of $7.65 billion, a price-to-earnings ratio of 383.59, a P/E/G ratio of 1.99 and a beta of 1.89.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Tuesday, February 5th. The company reported $0.19 EPS for the quarter, topping the Zacks’ consensus estimate of $0.14 by $0.05. Neurocrine Biosciences had a net margin of 4.68% and a return on equity of 5.32%. The business had revenue of $131.49 million during the quarter, compared to analysts’ expectations of $132.32 million. During the same quarter in the previous year, the company earned $0.07 EPS. The business’s quarterly revenue was up 39.1% compared to the same quarter last year. As a group, sell-side analysts expect that Neurocrine Biosciences, Inc. will post 1.77 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Zurcher Kantonalbank Zurich Cantonalbank Has $437,000 Position in Neurocrine Biosciences, Inc. (NBIX)” was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.themarketsdaily.com/2019/02/09/zurcher-kantonalbank-zurich-cantonalbank-has-437000-position-in-neurocrine-biosciences-inc-nbix.html.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2), which is used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trial for use in women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trial that is used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease.

Further Reading: How Do Front-End Loads Impact an Investment?

Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply